Impact of extracorporeal cytokine absorber and continuous real replacement therapy on plasma drug levels of Meropenem, Linezolid and Anidulafungin in critically ill surgical patients.

Phase 4

• Conditions: A41; Other sepsis

• Registration Number: DRKS00023684
• Lead Sponsor: Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Chirurgische Klinik

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2019-11-30
• Study Start: 2023-01-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 11

Inclusion Criteria

Septic Shock with Indikation for renal replacement therapy

Exclusion Criteria

-Age < 18y
-Without Indikation for maximal therapy (e.g. Prognostic limited disease)
-Heparininduced thrombocytopenia
-Thrombocytes <20.000/µl
-Patients under immunsuppressive therapy
and/or hydrocortison >200 mg/d
-Low immunofunction (CD4 <200 or neutropenia <1000/µl)
-Pregnancy or breast feeding patients
-AIDS (<200 CD4/µl)
-Terminal heart, real and/or hepatic failure

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Elimination of antibiotics by the cytokine absorber and measurement of the difference of the drug level between both study arms. Observation period 96h.<br>Measuring times: Expected maximum and minimum level.

Secondary Outcome Measures

Name	Time	Method
- Length of Stay in ICU and hospital. Observation period 60 days